Cancer Drugs Fund Consultation
On 31st October 2014 Cancer52 submitted its response to the NHS England Consultation: Proposals for a sustainable Cancer Drugs Fund. You...
top of page
National Cancer Patient Experience Survey 2014
The National Cancer Patient Experience Survey 2014 was published this morning. Our comment on its publication is here.
Cancer52 publishes Manifesto for the 2015 General Election
Cancer52, an alliance of 80 charities working in the field of rare and less common cancers is today (19th September 2014) publishing its...
Joint VBA Statement
The Joint VBA Statement, prepared alongside Genetic Alliance UK, which nearly half our members signed, was submitted on Friday 12th...
Cancer52 response to announcement of new investment for Cancer Drugs Fund
Cancer52 welcomes the new additional investment of £160 million in the Cancer Drugs Fund (CDF) announced by Health Secretary Jeremy Hunt...
NICE consultation on Review Guide to the Methods of Technology Appraisals Addendum
Cancer52 has commented on a number of aspects of the Methods of Technology Appraisals consultation, and submitted its response to NICE....
Cancer52 response to the NICE consultation
Please find here Cancer52's response to the NICE Methods of Technology Appraisal Consultation, which was submitted to NICE on Tuesday...
New report from Cancer52: percentage of cancer deaths outside the big four rises to 54%
A new report published today (Tuesday 10th June 2014) by Cancer52 shows that the percentage of cancer deaths from those cancers outside...
Briefing paper on Access to Orphan Medicines in the UK
On 5th June 2014, Cancer52 published its Briefing Paper on Access to Orphan Medicines in the UK.
Clara Mackay appointed as interim chair of Cancer52
Cancer52 is delighted to announce that Clara Mackay, Deputy CEO of Pancreatic Cancer UK, has been appointed as interim chair of Cancer52....
bottom of page